POST URS Chemotherapy Instillation

Launched by CARMEL MEDICAL CENTER · Dec 4, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the safety and effectiveness of a single chemotherapy treatment given directly into the bladder after a procedure called ureteroscopy (URS) for patients suspected of having upper tract urothelial carcinoma (UTUC), a type of cancer affecting the urinary system. The main goal is to see if this treatment can help reduce the chances of cancer returning in the bladder.

To participate in the trial, individuals need to be at least 18 years old and have some signs of UTUC based on imaging or lab tests. They must also plan to undergo a procedure to treat or diagnose UTUC. Eligible participants will receive the chemotherapy treatment within 24 hours after their ureteroscopy and will have follow-up appointments for monitoring. It’s important to note that certain patients, such as those with recent bladder cancer or certain treatments, may not be able to join. This trial is currently recruiting participants of all genders, and it aims to contribute valuable information about new treatment options for UTUC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Radiographic and/or cytological suspicion for UTUC
• • Planned endoscopic procedure for treatment / diagnosis of UTUC
• * Patients with bladder cancer history are eligible if meeting both following criteria:
• • No recurrence within the last two years Are not on active bladder irrigation protocol
• • Patients with history of UTUC are eligible if last endoscopic treatment or RNU was \>1 year prior to enrollment
• • Age ≥ 18 years
• • Performance status ECOG 0-2
• Exclusion Criteria:
• • Subjects who have had bladder / prostate radiotherapy
• • Subjects with bladder cancer history on active bladder irrigation protocols or with active disease within two years prior to enrollment
• • Subjects with previously treated UTUC within one year prior to enrollment
• • Subjects with metastatic disease